Update for investors of

BIOCON

is currently trading at Rs. 398.50, up by 6.35 points or 1.62% from its previous closing of Rs. 392.15 on the BSE. The scrip opened at Rs. 393.50 and has touched a high and low of Rs. 401.55 and Rs. 393.50 respectively. So far 44038 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 424.95 on 18-Nov-2025 and a 52 week low of Rs. 290.80 on 03-Mar-2025. Last one week high and low of the scrip stood at Rs. 401.55 and Rs. 383.70 respectively. The current market cap of the company is Rs. 53344.85 crore. The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 28.71% and 16.83% respectively. Biocon has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration (USFDA), for its Biocon Generics Inc facility, located in Cranbury, New Jersey, U.S. This is based on a cGMP inspection conducted by the agency between the October 6 to October 10, 2025. Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.